ClinicalTrials.gg
RecruitingNCT05888870Updated Feb 24, 2025

ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor

A Phase 4 interventional study of SCT800 and Daratumumab and SCT800 in Hemophilia A With Inhibitor, sponsored by Institute of Hematology & Blood Diseases Hospital, China. Recruiting at 1 site in China. Open to participants aged 14 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-02-24.

Sponsored by Institute of Hematology & Blood Diseases Hospital, China · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
14 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Hemophilia A by Institute of Hematology & Blood Diseases Hospital, China — 11 open to participants now, 12 under way, none of them phase 3. Hemophilia A · Institute of Hematology & Blood Diseases Hospital, China.

Started
2023
with 1 other
Phase 4
3 of 13
3 open now
Primary completion
2026-12
later than 4 of 11 live
Registered
8th of 13
by date

Among the 13 studies in Hemophilia A by Institute of Hematology & Blood Diseases Hospital, China, this one is one of 2 that started in 2023, is one of 3 in phase 4, reaches primary completion later than 4 of the 11 other live ones, and was the 8th registered.

Hemophilia A

845 studies on the registry are indexed under Hemophilia A; 137 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

11 of the 13 studies in Hemophilia A by Institute of Hematology & Blood Diseases Hospital, China are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

Who these studies take

Of the 88 Hemophilia A studies recruiting now, 52 (59%) set no upper age limit and 31 (35%) stop at 75 or younger; 56 take children under 18; 10 take healthy volunteers.

This study: 14 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Hemophilia A by Institute of Hematology & Blood Diseases Hospital, China, or all of them as a file.
02

Study summary

To evaluate the time of response, sustained remission rate, and relapse rate of CD38 monoclonal antibody (Daratumumab) combined with SCT800 (rFVIII) in the treatment of hemophilia A adolescents and adults with high titer inhibitors.

Read the detailed description

This is a non-randomized controlled trial to compare the outcome of immune tolerance induction therapy usingnon- SCT800 combined with Daratumumab or SCT800 alone in hemophilia A adolescents and adults with high titer inhibitors. Patients will receive Daratumumab combined with SCT800 or SCT800 alone.

03

Conditions studied

  • Hemophilia A With Inhibitor

Browse trials for

04

Who can participate

Ages eligible
14 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Moderate or severe hemophilia A;
  2. Aged 14-66 years old;
  3. Inhibitor positive at 2 consecutive visits;
  4. Inhibitor titer > 10 BU at the screening visit.

Exclusion criteria

Exclusion Criteria:

  1. The patient has to drug ingredients or hamster protein allergy;
  2. Suffering from other immune diseases or Using IS to treat another disease(s);
  3. Failed systemic ITI treatment in history;
  4. Poor patients compliance;
  5. The investigator believes that there are any other reasons that make the patient unsuitable to participate in this study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    SCT800 combined with Daratumumab

    ITI using low-dose domestic rFVIII (SCT800) (50IU/kg TIW) and treated with Daratumumab 8mg/kg 4-8 times. Other immunosuppressants could be added after 3 months.

    Drug: SCT800 and Daratumumab

  • Active comparator
    SCT800 alone

    ITI using low-dose domestic rFVIII (SCT800) (50IU/kg TIW) alone. Other immunosuppressants could be added after 3 months.

    Drug: SCT800

Interventions

06

What researchers measure

Primary outcomes

  1. success rate of ITI success rate of ITI success rate of ITI success rate of ITI

    Inhibitor titre \<0.6 BU⁄mL

    Time frame: 12 months

  2. Success rate and partial success rate of ITI after 3-month treatment

    Inhibitor titre \<0.6 BU⁄mL

    Time frame: 3 months

Secondary outcomes

  1. ITI success time

    time to successful tolerance

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Data can be requested from the corresponding authors from 12 months to 36 months after study completion

Supporting information: Study protocol

Time frame: from 12 months to 36 months after study completion

Access criteria: From corresponding author

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Dec 2026, 36 months after the start.

Of 40 phase 4 interventional studies under Hemophilia A, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 112. This study's planned 36 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2023
First posted
Jun 5, 2023
StartActual
Nov 22, 2023
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Feb 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05888870
Collaborators
Sinocelltech Ltd.
Responsible party
Sponsor
First posted
Jun 5, 2023
Start date
Nov 22, 2023
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Feb 24, 2025

Study contacts

Wei Liu
Contact
liuwei1@ihcams.ac.cn
+8613820261971
Lei Zhang
Contact
zhanglei1@ihcams.ac.cn
Lei Zhang
principal investigator · Chinese Academy of Medical Science and Blood Disease Hospital
Renchi Yang
principal investigator · Chinese Academy of Medical Science and Blood Disease Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Omfiloctocog alfa · Daratumumab

Start the discussion